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Abstract (120 words) 
Gemcitabine/cisplatin (GemCis) is standard of care for first-line treatment of patients with 
advanced biliary tract cancer (aBTC); new treatments are needed.  NUC-1031 is designed to 
overcome key cancer resistance mechanisms associated with gemcitabine.  The 
tolerability/efficacy signal of NUC-1031/cisplatin in the phase Ib ABC-08 study suggested 
this combination may represent a more efficacious therapy than GemCis for patients with 
aBTC, leading to initiation of the global NuTide:121 study which will include 828 patients 
≥18 years with untreated histologically/cytologically-confirmed aBTC (including 
cholangiocarcinoma, gallbladder, or ampullary cancer); randomised (1:1) to NUC‑1031 (725 
mg/m2)/cisplatin (25 mg/m2) or gemcitabine (1000 mg/m2)/cisplatin (25 mg/m2), on days 1/8, 
Q21-days. Primary objectives are OS and ORR. Secondary objectives: PFS, safety, 
pharmacokinetics, patient‑reported quality of life, and correlative studies. 
(Investigational New Drug (IND) number: 139058, European Clinical Trials Database: 
EudraCT Number 2019-001025-28, ClinicalTrials.gov: NCT04163900). 
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Biliary tract cancer (BTC) encompasses intrahepatic cholangiocarcinoma, originating from 
the bile ducts within the liver, extrahepatic cholangiocarcinoma (perihilar and distal 
cholangiocarcinoma), gallbladder and ampulla of Vater cancer [Nakeeb et al 1996, Valle et al 
2016, Overman et al 2013].  There are 11,980 estimated new cases, and 4,090 estimated 
deaths from gallbladder and BTCs (excluding intrahepatic cholangiocarcinoma) predicted in 
the United States in 2020 [Siegel et al 2020].  The majority of patients with BTCs present 
with advanced disease and potentially curative surgical resection is only possible in 
approximately 20% [Primrose et al 2019].  Standard of care treatment for patients with 
advanced disease is cisplatin plus gemcitabine, with a median overall survival (OS) reported 
of 11.7 months for this combination in the Advanced Biliary Cancer (ABC)-02 trial [Valle et 
al 2010], and of 13.04 months in a more recently reported trial [Valle et al 2020].  The 
objective response rate (ORR) reported for this combination in the first-line advanced BTC 
setting varies from 19.5% in the Japanese BT22 study [Okusaka et al 2010], to 26.1% in the 
ABC-02 study [Valle et al 2010] (both using Response Evaluation Criteria in Solid Tumours 
(RECIST) 1.0 [Therasse et al 2000], with radiological evaluation every 6 and 12 weeks 
respectively), and more recently 33% (RECIST 1.1) in a randomised phase II study 
(radiological evaluation every 6 weeks until 14 months and every 12 weeks thereafter) [Valle 
et al 2020]. 
Gemcitabine (a nucleoside analogue) has a high susceptibility to cancer cell resistance 
[Nakano et al 2007], and the addition of a phosphoramidate motif to gemcitabine may protect 
it against key resistance mechanisms [Slusarczyk et al 2014].  One of these phosphoramidate 
prodrugs is NUC-1031, and compared with gemcitabine is significantly less dependent on 
deoxycytidine kinase and nucleoside transporters and is resistant to cytidine-mediated 
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degradation [Slusarczyk et al 2014, Sarr et al 2019].  In a phase I dose escalation first-in-
human study of NUC-1031 in 68 patients with advanced solid tumours who had progressed 
after standard of care treatment [Blagden et al 2018], the recommended phase II dose (RP2D) 
in monotherapy was 825mg/m2 on days 1, 8 and 15 of a 28 day cycle.  It was well tolerated 
and clinically-significant anti-tumour activity was reported, including patients previously 
treated with gemcitabine and in cancers not traditionally considered gemcitabine-responsive 
[Blagden et al 2018].  The most common adverse reactions noted were reversible 
myelosuppression, gastrointestinal disturbance, fatigue and liver function enzyme elevation, 
not dissimilar to those observed with gemcitabine [Blagden et al 2018].  Seven patients with 
cholangiocarcinoma (primary site not specified) were included in this study, with 6 of these 
receiving ≥2 cycles of NUC-1031, and so were evaluable for efficacy assessment using 
RECIST 1.1 [Eisenhauer et al 2009]; the best response to therapy in 5 of these patients was 
stable disease (SD), with 3 showing target lesion size reduction [Blagden et al 2018]. 
Background and rationale 
The phase Ib ABC-08 trial (NCT02351765) was developed to determine the safety and the 
RP2D of NUC-1031 (starting dose 625mg/m2) in combination with cisplatin (25mg/m2) 
(administered day 1 and 8 of a 21 day cycle) in patients with advanced BTC in the first-line 
setting; secondary objectives included evaluation of ORR, progression-free survival (PFS) 
and OS and to undertake pharmacokinetic analyses.  In the interim analysis of ABC-08, the 
combination of NUC-1031 and cisplatin was well-tolerated over multiple cycles, with no 
unexpected adverse events, no dose-limiting toxicities, no discontinuations due to NUC-
1031-associated toxicity and no Grade 4 adverse events [McNamara et al 2018].  There were 
no differences in ORR or pharmacokinetics between the two doses of NUC-1031 (625 or 725 
mg/m2), thus the 725mg/m2 dose of NUC-1031 was selected as the RP2D in combination 
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with cisplatin in patients with advanced BTC for phase III evaluation in the first-line 
advanced setting, additionally allowing greater scope for dose reduction, if required. 
Based on data from the ABC-08 study, the global randomised phase III clinical study 
(NuTide:121) comparing NUC-1031 (725mg/m2) and cisplatin (25mg/m2) with gemcitabine 
(1,000mg/m2) and cisplatin (25mg/m2) (days 1 and 8 of a 21 day cycle) for the first-line 
treatment of patients with advanced BTC was initiated (NCT04163900) and further details 





The aim of this study is to compare the clinical activity and tolerability of NUC-1031 
administered with cisplatin against the current standard of care (gemcitabine in combination 
with cisplatin) in patients with locally advanced or metastatic BTC. 
NuTide:121 is an open-label, randomised phase III study of NUC-1031 in combination with 
cisplatin (Arm A) compared to gemcitabine in combination with cisplatin (Arm B), 
administered intravenously on days 1 and 8 of a 21 day cycle, in previously untreated patients 
with locally advanced or metastatic BTC. A total of 828 patients will be randomised in a 1:1 
ratio to Arm A or Arm B, and may continue to receive study treatment until documentation of 
disease progression, evidence of unacceptable treatment-related Adverse Events (AEs) 
despite optimal medical management and/or dose modification, or withdrawal of consent. 
Tumour measurements and disease response assessments are to be performed every 9 weeks 
(±7 days) (approximating three cycles) from Cycle 1, Day 1 until disease progression.  If the 
patient stops study treatment for reasons other than radiologically confirmed progressive 
disease (PD), tumour measurements and disease response assessments should continue every 
12 weeks (±14 days) thereafter until PD is radiologically confirmed.  This study will be 
conducted at approximately 120 sites across North America, Europe, and Asia-Pacific over 
30 months.  Target enrolment is 828 patients.  The study will continue until 637 deaths have 
occurred, unless the results for overall survival (OS) meet the pre-specified criterion at an 
interim analysis to stop for early demonstration of efficacy, or unless terminated early on the 





To be enrolled in this study, patients must meet all of the following criteria during the 
screening period: 
1. Written informed consent and authorisation to use and disclose health information. 
2. Ability to comprehend and willingness to comply with the requirements of the protocol, 
including the Quality of Life (QoL) questionnaires (European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 [Aaronson et al 
1993] with QLQ-BIL21 [Friend et al 2011] and EQ-5D-5 questionnaire [EQ-5D-5L Ref]). 
3. Female or male patients aged ≥18 years. 
4. Histologically- or cytologically-confirmed adenocarcinoma of the biliary tract (including 
gallbladder, intra and extra-hepatic biliary ducts and ampullary cancers) that is locally 
advanced, unresectable or metastatic.  Patients with measurable (as per RECIST 1.1 criteria 
[Eisenhauer et al 2009]) or non-measurable disease are permitted. 
5. Life expectancy ≥16 weeks. 
6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 
7. Adequate biliary drainage with no evidence of ongoing infection. If applicable, treatable 
and clinically-relevant biliary duct obstruction has been relieved by internal endoscopic 
drainage/stenting at least 2 weeks previously or by palliative bypass surgery or percutaneous 
drainage prior to study treatment, and the patient has no active or suspected uncontrolled 
infection.  Patients fitted with a biliary stent should be clinically stable and free of signs of 
infection for ≥2 weeks prior to study treatment.  Patients with improving biliary function who 
meet all other inclusion criteria may be re-tested during the screening window. 
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8. Adequate bone marrow, hepatic, and renal function, as evidenced by: 
• Absolute neutrophil count (ANC) ≥1,500/μL without colony-stimulating factor support. 
• Platelet count ≥100,000/μL. 
• Haemoglobin ≥10 g/dL without need for haematopoietic growth factor or transfusion 
support in prior 2 weeks. 
• Total bilirubin <2 × upper limit of normal (ULN); does not apply to patients with Gilbert's 
syndrome. Consistent with inclusion criterion 7, patients whose whole bilirubin and biliary 
function is recovering may be re-tested during the screening period. 
• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <5 × ULN. 
• Serum creatinine ≤1.5 × ULN or creatinine clearance ≥45 mL/min actual or calculated by 
the Cockcroft-Gault method. 
• International normalised ratio (INR) <1.5 and partial thromboplastin time (PTT) <1.5 × 
ULN; does not apply to patients on an anti-coagulant with stable dose 28 days prior to first 
dose. 
9. QTc interval <450 msec (males) or <470 msec (females), in the absence of bundle branch 
block.  In the presence of bundle branch block with consequent QTc prolongation, patients 
may be enrolled based on a careful risk-benefit assessment. 
10. Infected patients with Human Immunodeficiency Virus who are healthy and have a low 




11. Female patients of child-bearing potential (i.e. all women except those who are post-
menopausal for ≥1 year or who have a history of hysterectomy or surgical sterilisation) must 
have a negative pregnancy test within 3 days prior to the first study drug administration.  All 
patients of child-bearing potential must agree to practice true abstinence or to use two highly 
effective forms of contraception, one of which must be a barrier method of contraception, 
from the time of screening until 6 months after the last dose of study medication. 
12. Male patients with a female partner must either have had a successful vasectomy or they 
and their female partner meet the criteria above (not of childbearing potential or practicing 
highly effective contraceptive methods). 
Exclusion Criteria 
Patients who meet any of the following criteria at screening will be excluded from the study: 
1. Combined or mixed hepatocellular/cholangiocarcinoma. 
2. Prior systemic therapy for advanced or metastatic biliary tract cancer.  However, prior 
chemotherapy in the adjuvant setting or low-dose chemotherapy given in conjunction with 
radiotherapy in the adjuvant setting and completed at least 6 months prior to enrolment is 
permitted.  The following prior interventions are allowed provided the patient has fully 
recovered: 
• Surgery: non-curative resection with macroscopic residual disease or palliative bypass 
surgery.  Patients who have previously undergone curative surgery must now have evidence 
of non-resectable disease requiring systemic chemotherapy. 
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• Radiotherapy: prior radiotherapy (with or without radio-sensitising low-dose chemotherapy) 
for localised disease and there is now clear evidence of disease progression requiring 
systemic chemotherapy. 
• Photodynamic therapy: prior photodynamic therapy for localised disease with no evidence 
of metastatic disease or for localised disease to relieve biliary obstruction in the presence of 
metastatic disease, provided there is now clear evidence of disease progression requiring 
systemic chemotherapy. 
• Palliative radiotherapy: palliative radiotherapy provided that all AEs have resolved and the 
patient has measurable disease outside the field of radiation. 
3. Prior treatment with or known hypersensitivity to NUC-1031, gemcitabine, cisplatin or 
other platinum-based agents or history of allergic reactions attributed to the excipients 
contained in NUC-1031 or diluent solution (dimethylacetamide [DMA], Kolliphor ELP, 
Tween 80). 
4. Symptomatic central nervous system or leptomeningeal metastases. 
5. History of other malignancies, except adequately treated non-melanoma skin cancer, 
curatively treated in situ cancer of the cervix, low grade prostate cancer not requiring 
treatment or other solid tumours curatively treated with no evidence of disease for ≥3 years. 
6. Concurrent serious (as deemed by the investigator) medical conditions, including, but not 
limited to, New York Heart Association class III or IV congestive heart failure, history of 
congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other 




7. Other acute or chronic medical, neurological, or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or investigational 
product administration or may interfere with the interpretation of study results and, in the 
judgment of the investigator, would make the patient inappropriate for entry into this study. 
8. Prior exposure to another investigational agent within 28 days prior to randomisation. 
9. Major surgery within 28 days prior to randomisation; patient must have completely 
recovered from any prior surgical or other procedures. 
10. Pregnant or breastfeeding. 
11. Residual toxicities from prior treatments or procedures which have not regressed to Grade 
≤1 severity (Common Terminology Criteria for Adverse Events (CTCAE) v5.0), except for 
alopecia or ≤Grade 2 peripheral neuropathy. 
12. Concomitant use of drugs at doses known to cause clinically relevant prolongation of 
QT/QTc interval (see Appendix 1). 
13. Administration of a live vaccination within 28 days prior to randomisation. 
14. Ongoing or recent (≤6 months) hepatorenal syndrome. 
Planned sample size and study period: 
For overall survival (OS), a hazard ratio of 0.76 has been assumed.  With 3 looks (at 67%, 
85%, and 100% of the required number of OS events as described in Supplementary Table 1), 
use of the Lan-DeMets O'Brien-Fleming-like α-spending function (Lan & DeMets, 1983), an 
overall α=0.020 one-sided, and 1:1 randomisation, then a total of 637 OS events gives 90.9% 
power (after allowing for the small power loss from having the futility boundary).  Initially, 
α=0.020 one-sided is assigned to OS and α=0.005 one-sided is assigned to ORR. 
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A thirty-month duration of enrolment is assumed with gradual ramp-up over the first 12 
months (as described in the Statistical Analysis Plan (SAP)). Overall survival events are 
assumed to follow an exponential distribution, and a 11.7 month median has been assumed 
for the control arm as seen in the gemcitabine in combination with cisplatin arm in the ABC-
02 trial [Valle et al, 2010]. The hazard ratio of 0.76 then gives a median of approximately 
15.4 months in the NUC-1031 in combination with cisplatin arm (Arm A).  If the rate of 
discontinuation of treatment and the rate of discontinuation from the study (for Arm A and 
for Arm B) are both assumed to be comparable to the gemcitabine in combination with 
cisplatin arm from ABC-02, then 811 patients would result in the last of the 637 events 
occurring at approximately 48 months.  It is also assumed that 2% of patients will be lost to 
follow-up for OS (with unknown status of dead/alive) and so 828 patients will be 
randomised. 
If the study has not stopped with demonstration of efficacy, then a power reassessment will 
be carried out at Interim Analysis 3 (Supplementary Table 1), which is scheduled to occur 
after 541 OS events.  This power reassessment will use the CHW method [Cui et al, 1999], 
which guarantees that the maximum experiment wise Type 1 error will still be controlled at 
the required level.  The SAP will provide additional details on the procedure that will be used 
to implement the CHW method, including details on the maximum increase in number of OS 
events. 
For ORR, a 19% rate is assumed for the control arm. The derivation of this rate from the 
gemcitabine in combination with cisplatin arms within ABC-02 [Valle et al 2010], BT-22 
[Okusaka et al 2010], and ABC-03 [Valle et al 2015] studies (allowing for the requirement of 
confirmation, based on patients with ECOG performance status 0 or 1 only, including all 
randomised patients in the denominator, excluding patients with non-measurable disease at 
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baseline, and adjusting for use of BICR rather than investigator assessment) is provided in the 
SAP.  For the NUC-1031 in combination with cisplatin arm (Arm A), a 31% ORR is 
assumed, which gives an assumed true odds ratio of 1.92. 
With 2 looks for ORR (at 65% and 100% as described in Supplementary Table 2), use of the 
Lan-DeMets O'Brien-Fleming-like α-spending function (Lan & DeMets, 1983), and with an 
overall α=0.005 one-sided, then a total of 644 patients with measurable disease at baseline 
(together with 418 at the interim analysis) gives 80% power.  The two looks will take place 
28 weeks (corresponding to three scheduled post-baseline radiographic scans plus a one week 
visit window) after the last of these required numbers of patients have been randomised.  The 
number of randomised patients in the stratum for non-measurable disease at baseline is 
capped at 82 patients (~10%), which therefore gives at least 746 randomised patients in the 
measurable disease at baseline stratum. 
There are dual primary endpoints: OS and ORR.  The study would be viewed as positive (in 
terms of the primary efficacy endpoints) if statistical significance is obtained on either of the 
two primary endpoints. 
Subgroup analyses: 
For OS, numbers of events by treatment group, together with hazard ratios (derived from an 
unstratified Cox proportional hazards model with a single term for treatment within the 
model) will be provided separately for each of the following subgroups: 
• Primary tumour site: gallbladder, intra-hepatic, extra-hepatic, ampulla of Vater cancer 
• Stage of disease at baseline: metastatic disease, locally advanced disease 
• ECOG Performance Status (at baseline): 0, 1 
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• Region: Asia, non-Asia (with non-Asia also subdivided and provided separately for North 
America/Western Europe/Australasia combined, and for Central/Eastern Europe/rest of the 
World combined) 
• Gender: Male, Female 
• Age (at baseline): <65 years, ≥65 years 
• Measurable disease at baseline: yes, no 
For ORR, analyses in terms of estimates (of ORR, as well as counts for complete response 
(CR) and for partial response (PR)) by treatment group, together with odds ratios, difference 
in proportions of patients with ORR will be given for each of the following subgroups: 
• Primary tumour site: gallbladder, intra-hepatic, extra-hepatic, ampulla of Vater cancer 
• Stage of disease at baseline: metastatic disease, locally advanced disease 
Study procedures: 
Patients will be randomised in this study from approximately 120 sites in North America, 
Europe, and Asia Pacific.  Patients will be randomised to receive either: 
• NUC-1031 plus cisplatin (Arm A), or 
• Gemcitabine plus cisplatin (Arm B) 
In Arm A, cisplatin will be administered by intravenous (IV) infusion at 25 mg/m2 over 60 
minutes followed by IV infusion of NUC-1031 at 725 mg/m2 over 30 minutes on days 1 and 
8 of each 21 day cycle.  In Arm B, cisplatin will be administered by IV infusion at 25 mg/m2 
over 60 minutes followed by IV infusion of gemcitabine at 1000 mg/m2 over 30 minutes on 
days 1 and 8 of each 21 day cycle.  Tumour measurements and disease response assessments 
16 
 
are to be performed every 9 weeks (±7 days) (approximating three cycles) from Cycle 1 Day 
1 until disease progression.  Objective disease assessment will be performed by radiologic 
evaluation and assessed according to RECIST 1.1 criteria.  All known or suspected disease 
sites must be assessed at baseline by either computed tomography (CT), magnetic resonance 
imaging (MRI) or positron emission tomography CT (PET-CT) scan.  For each patient, the 
same radiological method used at baseline must be used for disease assessment throughout 
the duration of the patient’s participation in the study. 
Patients may continue to receive study treatment until documentation of objective progressive 
disease, evidence of unacceptable treatment-related AEs, despite optimal medical 
management and/or dose modification, or withdrawal of consent. Reasons for treatment 
discontinuation will be captured in the patient medical record and on the treatment 
discontinuation page of the case report form (CRF). 
A patient who is receiving clinical benefit, but experiencing toxicity related to the cisplatin 
component may continue on study receiving single agent NUC-1031 (Arm A) or gemcitabine 
(Arm B).  If a patient discontinues treatment without radiological evidence of disease 
progression, they should continue to undergo tumour assessment every 12 weeks (±14 days) 
until such time as progression can be documented or new treatment is initiated.  Patients who 
stop treatment following an unconfirmed response should also still have a confirmatory scan 
within the 28- to 42-day window, if the scan can take place prior to the patient starting any 
subsequent anti-cancer therapies.  Following discontinuation of study treatment, patients will 
receive treatment in accordance with local standard of care. 




• Overall Survival. 
• Objective Response Rate based on blinded independent central review (BICR) in patients 
with measurable disease at baseline. 
Secondary Objectives 
• Progression-free survival (PFS) based on BICR. 
• Duration of response (DoR) based on BICR. 
• 18- and 12-month survival. 
• Disease Control Rate (DCR) based on BICR. 
• Safety. 
• Pharmacokinetics of NUC-103. 
• Patient-reported Quality of Life. 
Tertiary Objectives 
• Health economics. 
• Assessment of archival tumour sample characteristics that may further an understanding of 
the mechanism(s) through which the clinical activity of NUC-1031 is achieved. 
Primary Endpoints: 




• Objective Response Rate, defined as the percentage of patients achieving a confirmed CR or 
PR to treatment, as assessed by BICR according to RECIST 1.1 criteria [.  This will be 
assessed only in patients with measurable disease at baseline. 
Secondary Endpoints: 
Key Secondary Endpoint 
• Progression-free survival, based on BICR according to RECIST 1.1 criteria [Eisenhauer et 
al 2009] defined as the time from randomisation to the first observation of objective tumour 
progression or death from any cause.  Assessment of progression for the purposes of 
measuring PFS in patients with non-measurable disease will be performed according to 
RECIST 1.1 recommendations [Eisenhauer et al, 2009]. 
Other Secondary Endpoints: 
Efficacy 
• Duration of Response, as assessed by BICR, defined as the time from initial clinical 
response, PR or CR that is subsequently confirmed, to the first observation of tumour 
progression or death from any cause. 
• 18-month survival. 
• 12-month survival. 
• Disease Control Rate, based on BICR according to RECIST 1.1 criteria [Eisenhauer et al, 




Objective disease assessment will be performed radiologically and assessed according to 
RECIST 1.1 criteria [Eisenhauer et al, 2009].  Treatment and study continuation decisions 
based on radiologic assessments will be made by the treating investigator. 
Safety 
Safety and tolerability will be assessed by evaluation of the following: 
• Treatment emergent adverse events (TEAEs), including TEAEs by severity grade using 
Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 
• Serious TEAEs (SAEs). 
• Deaths due to TEAEs. 
• Treatment discontinuations due to TEAEs. 
• Clinically significant changes in laboratory parameters. 
• Changes in ECOG performance status, physical exam, electrocardiogram (ECG) and vital 
signs. 
A sub-study will be carried out to assess the effect of the NUC-1031 + cisplatin combination 
on cardiac repolarisation in a subset of patients. 
Pharmacokinetics (PK) of NUC-1031 
Sparse PK sampling will be taken on Cycle 1 Day 1 at the end of infusion, 2 hours after the 
end of infusion, and 6 hours after the end of infusion, to capture Ctrough and Cmax plasma 
levels. 
Patient-Reported Quality of Life 
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Patient-reported QoL will be assessed using the European Organisation for Research and 
Treatment (EORTC) QoL Questionnaire (QLQ-C30) [Aaronson et al 1993] QLQ-BIL21 




Health economics will be assessed through collection of core health resource use information 
using CRFs to capture procedure codes, days in hospital, and outpatient visits. Health 
outcomes will be quantified using quality-adjusted life years (QALYs) and a cost-utility 
analysis will be conducted by creating incremental cost-utility ratios for each of the treatment 
groups. 
Biomarkers 
Phenotypic, genotypic, and/or pharmacodynamic characteristics of the tumour cell that may 
further delineate the mechanism(s) through which NUC-1031 acts. 
Statistics 
Full details of the planned analyses will be provided in a separate SAP. The statistical 
principles applied in the design and planned analyses of this study are consistent with ICH E9 
[Ref] and FDA Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer 
Drugs and Biologics (2018) [Ref]. 
The following sections define the populations that will be used for statistical analyses. 
Intention-to-Treat (ITT) Population 
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The ITT population will consist of all patients who are randomised, regardless of whether any 
study medication was received.  Patients will be summarised on the basis of the treatment 
group to which they were randomised. 
Intention-to-Treat with Measurable Disease at Baseline (ITTMD) Population 
The ITTMD population will consist of all patients who are randomised to the stratum 
corresponding to having measurable disease at baseline (as assessed by BICR), regardless of 
whether any study medication was received.  Patients will be summarised on the basis of the 
treatment group to which they were randomised. 
Modified Intention-to-Treat (MITT) Population 
The MITT population will consist of all patients who are randomised and received any study 
medication.  Patients will be summarised on the basis of the treatment group to which they 
were randomised. 
Safety Population 
The safety population will consist of all patients who are randomised and receive any study 
medication.  Patients will be summarised on the basis of the actual study medication received, 
i.e. NUC-1031 in combination with cisplatin (Arm A), or gemcitabine in combination with 
cisplatin (Arm B).  Any patients receiving study medication from both arms will be 
summarised under Arm A. 
Primary Analysis Populations 
The ITTMD will be the primary analysis population for evaluating ORR and DCR.  Duration 
of Response will be analysed in the subset of ITTMD patients who have confirmed response. 
For evaluating all other efficacy endpoints, the primary analysis population will be the ITT 
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population.  The MITT population will be used only for a secondary analysis of the OS 
primary endpoint. The safety population will be the primary analysis population for 
evaluating all safety endpoints. 
Patient Disposition 
For the ITT population, counts and percentages will be provided by treatment group for each 
of the following: treated or untreated; treatment ongoing or treatment ended; primary reason 
for end of treatment; and whether the patient discontinued the study overall and by reason. 
For each treatment group, the number of patients in each analysis population will be 
summarised.  Major protocol deviations (as defined in a separate Protocol Deviation 
Management Plan) will also be summarised by reason and overall. 
Demographics and baseline characteristics 
Demographic and baseline characteristics will be summarised by treatment group for the ITT, 
ITTMD, and safety populations.  Full details on the variables summarised will be provided 
within the SAP. 
Three interim efficacy analyses are planned in addition to the final analysis. 
• The first interim analysis (Interim Analysis 1) will evaluate the ORR primary endpoint.  It 
will be performed 28 weeks after 418 patients in the measurable disease stratum have been 
randomised.  At this interim, a futility analysis will also be conducted for OS and it is 
estimated that approximately 258 deaths will be observed by this time. 
• The second interim analysis (Interim Analysis 2) will evaluate the ORR and OS primary 
endpoints.  It will be the final analysis for ORR and the first interim analysis (for 
demonstration of efficacy) of OS.  It will be performed 28 weeks after 644 patients in the 
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measurable disease stratum have been randomised.  It is estimated that approximately 425 
deaths will be observed by this time. 
• The third interim analysis (Interim Analysis 3) will evaluate the OS primary endpoint for 
which it will be the second interim analysis (for demonstration of efficacy).  It will take place 
after 541 deaths have been observed. 
• The final analysis will evaluate the OS primary endpoint.  It will take place after 637 deaths 
have been observed, and is expected to occur approximately 48.0 months after the first 
patient is randomised. 
Progression-free survival, the key secondary endpoint, will also be assessed at Interim 
Analysis 2 and approximately 534 patients are expected to have a PFS event at this time. 
A summary of the planned analyses for demonstration of efficacy, with timings and primary 
endpoints to be evaluated, is given in Supplementary Table 3. 
If ORR crosses its efficacy boundary at Interim Analysis 1, and provided that a further 
assessment of ORR is not required by regulators, then the driver of timing for Interim 
Analysis 2 will instead be the occurrence of 425 OS events.   For further information on Type 
1 error control across the Interim Analyses and across the multiple endpoints, see 
supplementary material 1. 
Institutional Review Boards (IRBs)/ Ethics Committees (ECs) 
The applicable IRBs/ECs will review all appropriate study documentation in order to 
safeguard the rights, safety, and wellbeing of the patients.  The final study protocol and 
informed consent form will be approved in writing by the applicable IRBs/ECs for each site.  
Authorisation to conduct the study will be obtained from the applicable Regulatory 
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Authorities prior to initiating the study in each participating country.  All patients are 
required to give written informed consent before randomisation and the trial will be 




The phase III open-label, multi-centre, randomised study comparing NUC-1031 plus cisplatin 
to gemcitabine plus cisplatin in patients with previously untreated locally advanced or 
metastatic biliary tract cancer (NuTide:121) is open to recruitment.  This study will be 
conducted at approximately 120 sites across North America, Europe, and Asia-Pacific over a 
30 month duration, recruiting 828 patients.  There are dual primary endpoints: OS and ORR.  
The study would be viewed as positive (in terms of the primary efficacy endpoints) if 




 Standard of care first-line treatment for patients with advanced biliary tract cancer is 
the gemcitabine/cisplatin combination, resulting in a median overall survival of less 
than 1 year. 
 New therapeutic combinations are required. 
 Efficacy of gemcitabine is limited by cancer cell resistance mechanisms. 
 A phosphoramidate modification of gemcitabine, NUC-1031 was designed to 
overcome these key gemcitabine resistance mechanisms. 
 In a first-in-human study, including 7 patients with cholangiocarcinoma, NUC-1031 
was well tolerated and demonstrated clinically significant anti-tumour activity in 
patients with previously treated advanced solid tumours. 
 The ABC-08 study determined that the recommended phase 2 dose of NUC-1031 in 
combination with cisplatin in the first-line setting in patients with advanced biliary 
tract cancer was 725mg/m2. 
 This resulted in the development of the global randomised phase III clinical study 
(NuTide:121) comparing NUC-1031 (725mg/m2) and cisplatin (25mg/m2) with 
gemcitabine (1,000mg/m2) and cisplatin (25mg/m2) (days 1 and 8 of a 21 day cycle) 
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NuTide:121 study schema 
CR; Complete response, PR: Partial response, RECIST: Response evaluation criteria in 
solid tumours.  Patients who stop treatment with no evidence of disease progression as 
defined by RECIST 1.1 criteria [Eisenhauer et al 2009] will continue to have scans every 12 
weeks (±14 days) until disease progression in order to determine duration of overall response 
and progression-free survival. 
Supplementary Figure 1 
Type 1 error recycling between the two primary endpoints and the key secondary endpoint 
ORR: Overall response rate, PFS: Progression-free survival, OS: Overall survival 
 
 
 
 
 
